ישראל - עברית - Ministry of Health

medici medical ltd, israel - a/michigan/45/2015 (h1n1)pdm09-like virus; a/singapore/infimh-16-0019/2016 (h3n2) - like virus; b/colorado/06/2017- like virus (b/victoria/2/87 lineage); b/phuket/3073/2013 - like virus (b/yamagata/16/88 lineage) - תרחיף להזרקה - b/phuket/3073/2013 - like virus (b/yamagata/16/88 lineage) 15 mcg/dose; a/michigan/45/2015 (h1n1)pdm09-like virus 15 mcg/dose; a/singapore/infimh-16-0019/2016 (h3n2) - like virus 15 mcg/dose; b/colorado/06/2017- like virus (b/victoria/2/87 lineage) 15 mcg/dose - influenza, inactivated, whole virus - influenza, inactivated, whole virus - for the prevention of influenza.

ישראל - עברית - Ministry of Health

neopharm scientific ltd - a/brisbane/02/2018(h1n1)pdm09-like virus; a/kansas/14/2017 (h3n2) like virus; b/colorado/06/2017- like virus (b/victoria/2/87 lineage); b/phuket/3073/2013 (b/yamagata lineage)-like virus - תרחיף להזרקה - b/phuket/3073/2013 (b/yamagata lineage)-like virus 15 mcg / 0.5 ml; b/colorado/06/2017- like virus (b/victoria/2/87 lineage) 15 mcg / 0.5 ml; a/kansas/14/2017 (h3n2) like virus 15 mcg / 0.5 ml; a/brisbane/02/2018(h1n1)pdm09-like virus 15 mcg / 0.5 ml - influenza, inactivated, split virus or surface antigen - influenza, purified antigen - prophylaxis of influenza.

ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - ספריי לאף - b/phuket/3073/2013 (b/yamagata lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/darwin/9/2021 (h3n2)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 7 ±0.5 log10 ffu^a / 0.2 ml - influenza, inactivated, split virus or surface antigen - influenza, purified antigen - flumist quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza a subtype viruses ad type b viruses contained in the vaccine. flumist quadrivalent is approved for use in persons 2 through 49 years of age.

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd, israel - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - תרחיף להזרקה - b/phuket/3073/2013 (b/yamagata lineage)-like virus 30 mcg ha / 1 ml; a/darwin/9/2021 (h3n2)-like virus 30 mcg ha / 1 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 30 mcg ha / 1 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 30 mcg ha / 1 ml - influenza, inactivated, split virus or surface antigen

ישראל - עברית - Ministry of Health

sanofi israel ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - תרחיף להזרקה - b/phuket/3073/2013 (b/yamagata lineage)-like virus 30 mcg ha / 1 ml; a/darwin/9/2021 (h3n2)-like virus 30 mcg ha / 1 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 30 mcg ha / 1 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 30 mcg ha / 1 ml - influenza, inactivated, split virus or surface antigen

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - תרחיף להזרקה - b/phuket/3073/2013 (b/yamagata lineage)-like virus 30 mcg ha / 1 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 30 mcg ha / 1 ml; a/darwin/9/2021 (h3n2)-like virus 30 mcg ha / 1 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 30 mcg ha / 1 ml - influenza, inactivated, split virus or surface antigen

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd, israel - a/cambodia/e0826360/2020 (h3n2)-like strain; a/victoria/2570/2019 (h1n1)pdm09-like strain; b/washington/02/2019 (b/victoria lineage)-like virus - תרחיף להזרקה - b/washington/02/2019 (b/victoria lineage)-like virus 15 mcg/dose / 0.5 ml; a/cambodia/e0826360/2020 (h3n2)-like strain 15 mcg / 0.5 ml; a/victoria/2570/2019 (h1n1)pdm09-like strain 15 mcg / 0.5 ml - influenza, inactivated, split virus or surface antigen - influenza, inactivated, whole virus - influenza virus vaccine.

ישראל - עברית - Ministry of Health

sanofi israel ltd - a/michigan/45/2015 (h1n1)pdm09 – like strain; a/singapore/infimh-16-0019/2016 (h3n2) - like virus; b/colorado/06/2017- like virus (b/victoria/2/87 lineage); b/phuket/3073/2013 like strain - תרחיף להזרקה - b/phuket/3073/2013 like strain 60 mcg / 0.7 ml; b/colorado/06/2017- like virus (b/victoria/2/87 lineage) 60 mcg / 0.7 ml; a/singapore/infimh-16-0019/2016 (h3n2) - like virus 60 mcg / 0.7 ml; a/michigan/45/2015 (h1n1)pdm09 – like strain 60 mcg / 0.7 ml - influenza, inactivated, split virus or surface antigen

ישראל - עברית - Ministry of Health

devries & co. ltd - exemestane - טבליות מצופות פילם - exemestane 25 mg - exemestane

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.